The US Food and Drug Administration has granted approval for Teva Pharmaceutical Industries' ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately.
Teva's Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis' Desferal for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.
Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.